The announcement by Medtronic that the SYMPLICITY HTN-3 trial failed to meet its primary effectiveness end point calls the blood pressure lowering effects of renal denervation into question. However, its safety is proven, which raises the possibility that the procedure might have beneficial effects on the kidneys beyond blood pressure reduction.
